Entrada Therapeutics opened lower at $5.33, compared with its previous close of $5.44. In the last trading session, the stock traded between $4.94 and $5.43. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Entrada Therapeutics is now worth
$ 15.94
Resulting in a loss of
$ 84.06 (84.06%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
$-0.25 (-4.65%)
Day High
$5.43
Day Low
$4.94
Day Open
$5.33
Prev Close
$5.44
Volume
6,97,069
1W Return
2.57%
1M Return
-5.79%
3M Return
-26.28%
6M Return
-25.90%
1Y Return
-32.64%
Fundamentals
Market Cap ($ Mn)
203
PE Ratio
-
PB Ratio
1.17
PEG Ratio
-
ROE
-38.39%
ROCE
-37.14%
EPS (TTM)
$-1.02
Investment Returns
1 Week
2.57%
1 Month
-5.79%
3 Months
-26.28%
6 Months
-25.90%
9 Months
-53.14%
Financials
Quarterly
All values in $ Mn
20.6
Mar 25
1.9
Jun 25
1.6
Sep 25
1.3
Dec 25
0.9
Jun 26
0.9
Sep 26
Updates
14Oct
Entrada Therapeutics shares fall 15% on early Duchenne trial data
Entrada Therapeutics shares fell 15.23% following Phase 1/2 trial results. First cohort showed 0.10% mean increase in dystrophin production vs baseline. Safety profile was favorable with no discontinuations or renal concerns. Next data readout for 10 mg/kg dose expected in first half of 2027.
29 days ago
14Oct
Entrada Therapeutics advances DMD trial to top dose of 18 mg/kg
Entrada Therapeutics initiated Cohort 3 of ELEVATE-44-201 at 18 mg/kg. DMC reviewed safety and PK data from eight participants in Cohort 2. Dose increased from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1. Study targets Duchenne muscular dystrophy patients with exon 44 skipping mutations.
29 days ago
3Sep
Entrada Therapeutics grants equity awards to eight new hires
Entrada Therapeutics granted 61,365 RSUs and options for 19,425 shares to eight new employees. Stock options have an exercise price of $7.07, equal to the closing price on August 31, 2026. Awards were approved under Nasdaq Listing Rule 5635(c)(4) as material inducements for employment. RSUs vest quarterly at 6.25% after a one-year cliff, while options vest monthly over three years post-cliff.
2mo ago
8Jun
Guggenheim maintains Buy on Entrada Therapeutics, cuts target to $17
Guggenheim analyst Debjit Chattopadhyay maintains a Buy rating on Entrada Therapeutics (NASDAQ: TRDA) but lowers the price target to $17 from $20, adjusting the valuation outlook.
